X-twitter Linkedin Facebook-f Vimeo

Health

Companies engaged in biotechnology, pharmaceuticals, research services, home healthcare, hospital operations, long‑term care, and the manufacture and supply of medical equipment and supplies. The sector also includes pharmaceutical retailers and providers of health‑information services. UK‑listed companies in this sector include AstraZeneca plc, GlaxoSmithKline plc, Smith & Nephew plc, Hikma Pharmaceuticals plc, ConvaTec Group plc, Spire Healthcare plc and EMIS Group plc.

AstraZeneca

AstraZeneca and Ionis’ Wainua misses Phase III ATTR-CM trial endpoint

The CARDIO-TTRansform Phase III trial1 for AstraZeneca and Ionis' Wainua (eplontersen) in patients with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) did not meet the primary efficacy.....
Biotech Growth Trust

Biotech Growth Trust: The biotech rebound powered by innovation, valuations and pharma’s patent cliff

Biotech Growth Trust gives UK investors access to a global biotech sector where Geoffrey Hsu sees a rare combination of scientific innovation, attractive valuations, supportive regulation and renewed M&A momentum...
Verici Dx Plc

Verici Dx strengthens the case for RNA-based kidney transplant diagnostics

Verici Dx is using multicentre clinical data to support RNA-based diagnostics for kidney transplant risk assessment...
Genflow Biosciences Plc

Gene research sharpens the case for targeted biotechnology

Genflow’s focus on SIRT6 highlights how gene science is shaping more targeted approaches to ageing and age-related disease...
EDX Medical Group plc

EDX Medical builds momentum around precision cancer testing

EDX Medical is advancing precision cancer diagnostics through large-scale prostate testing in Scotland, AIM market access and a wider commercial rollout of disease detection products...
Cizzle Biotechnology Holdings plc

Cizzle Bio sharpens focus on earlier lung cancer detection

Cizzle Bio is advancing a minimally invasive blood test aimed at helping lung cancer be detected earlier...
BIOG

Turning scientific breakthroughs into investable commercial opportunities

Scientific breakthroughs become commercially relevant when strong research is matched with scalable infrastructure, business discipline and a clear route to adoption...
BIOG

Why biotech cycles can open timely growth opportunities

Biotech cycles can create attractive opportunities when lower valuations meet advancing science, upcoming clinical milestones, and strong strategic demand from large pharmaceutical companies...
Verici Dx Plc

Verici Dx gains nationwide access for kidney transplant test

Verici Dx has secured New York State approval for Tutivia, giving the kidney transplant rejection risk test nationwide US access...
Genflow Biosciences Plc

Genflow Biosciences prepares for key longevity data

Genflow Biosciences is set to present full dog longevity study results that could shape its animal health strategy and partnership prospects...
Biotech Growth Trust Plc

Biotech Growth Trust Plc – Annual Report Snapshot 2026

Visit Biotech Growth Trust Plc’s 2026 Annual Report page to review returns, financial highlights, portfolio commentary, KPIs, historic performance and Chair’s statement...
intravenous (IV) line

AstraZeneca and Daiichi Sankyo’s Datroway recommended for EU approval in metastatic TNBC

Astrazeneca Plc says CHMP has recommended Datroway for EU approval as first-line treatment in metastatic triple-negative breast cancer...
VRCI

Verici Dx reports full-year growth in Tutivia revenues and FY25 final results

Verici Dx reported higher annual revenues, first Tutivia sales and continued commercial progress, alongside a post-period equity fundraise...
ETHY

Ethtry reports strengthened balance sheet in 2025 results

Ethtry reported a 2025 loss of £619,270, while cash increased to £4.3 million following a £5.3 million fundraising, supporting its renewable energy strategy and post-year-end Ethereum treasury rollout...
BIOG

Praxis Precision Medicines wins FDA Breakthrough Status for rare epilepsy treatment

Praxis Precision Medicines has received FDA Breakthrough Therapy Designation for elsunersen, adding momentum to a rare epilepsy programme held in Biotech Growth Trust’s portfolio...
Cizzle Biotechnology Holdings plc

Cizzle Bio targets earlier detection in gastric cancer

Cizzle Bio is targeting the gastric cancer diagnostic gap with DEX-G2, a blood test designed to support earlier detection where routine screening is limited...
SPI

Spire Healthcare Group Plc Spire Healthcare receives further extension to PUSU deadline

Spire Healthcare says discussions with Toscafund continue, with the Takeover Panel consenting to a further extension of the offer deadline...
VRCI

Verici Dx secures New York State laboratory certification for Tutivia test

Verici Dx has obtained New York State clinical laboratory certification, completing authorisation for Tutivia across all 50 US states and the District of Columbia...
CIZ

Dr Allan Syms on Cizzle Biotechnology’s CIZ1B US accreditation

Cizzle Biotechnology Executive Chairman Dr Allan Syms discusses the CIZ1B early lung cancer test gaining CLIA accreditation in the US, marking a shift towards commercial adoption, royalty revenues, and wider..
Genflow Biosciences Plc

Healthspan becomes a clearer investment theme in preventive wellness

Healthspan is becoming a stronger investment theme as consumers focus on daily habits that support healthier ageing...

News and Interview Alerts

Subscribe Free

Company Presentations

Q&As

Hardman & Co

Green News

View all Sustainable sectors, Plcs and news >>  

Search

Search

Latest Interviews

BrokerTalk

Funds

View all Funds, Market Insights and news >> 

FTSE 100 News

UK Broker Ratings

Health

AstraZeneca

AstraZeneca and Ionis’ Wainua misses Phase III ATTR-CM trial endpoint

The CARDIO-TTRansform Phase III trial1 for AstraZeneca and Ionis' Wainua (eplontersen) in patients with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) did not meet the primary efficacy.....
Biotech Growth Trust

Biotech Growth Trust: The biotech rebound powered by innovation, valuations and pharma’s patent cliff

Biotech Growth Trust gives UK investors access to a global biotech sector where Geoffrey Hsu sees a rare combination of scientific innovation, attractive valuations, supportive regulation and renewed M&A momentum...
Verici Dx Plc

Verici Dx strengthens the case for RNA-based kidney transplant diagnostics

Verici Dx is using multicentre clinical data to support RNA-based diagnostics for kidney transplant risk assessment...
Genflow Biosciences Plc

Gene research sharpens the case for targeted biotechnology

Genflow’s focus on SIRT6 highlights how gene science is shaping more targeted approaches to ageing and age-related disease...
EDX Medical Group plc

EDX Medical builds momentum around precision cancer testing

EDX Medical is advancing precision cancer diagnostics through large-scale prostate testing in Scotland, AIM market access and a wider commercial rollout of disease detection products...
Cizzle Biotechnology Holdings plc

Cizzle Bio sharpens focus on earlier lung cancer detection

Cizzle Bio is advancing a minimally invasive blood test aimed at helping lung cancer be detected earlier...
BIOG

Turning scientific breakthroughs into investable commercial opportunities

Scientific breakthroughs become commercially relevant when strong research is matched with scalable infrastructure, business discipline and a clear route to adoption...
BIOG

Why biotech cycles can open timely growth opportunities

Biotech cycles can create attractive opportunities when lower valuations meet advancing science, upcoming clinical milestones, and strong strategic demand from large pharmaceutical companies...
Verici Dx Plc

Verici Dx gains nationwide access for kidney transplant test

Verici Dx has secured New York State approval for Tutivia, giving the kidney transplant rejection risk test nationwide US access...
Genflow Biosciences Plc

Genflow Biosciences prepares for key longevity data

Genflow Biosciences is set to present full dog longevity study results that could shape its animal health strategy and partnership prospects...
Biotech Growth Trust Plc

Biotech Growth Trust Plc – Annual Report Snapshot 2026

Visit Biotech Growth Trust Plc’s 2026 Annual Report page to review returns, financial highlights, portfolio commentary, KPIs, historic performance and Chair’s statement...
intravenous (IV) line

AstraZeneca and Daiichi Sankyo’s Datroway recommended for EU approval in metastatic TNBC

Astrazeneca Plc says CHMP has recommended Datroway for EU approval as first-line treatment in metastatic triple-negative breast cancer...
VRCI

Verici Dx reports full-year growth in Tutivia revenues and FY25 final results

Verici Dx reported higher annual revenues, first Tutivia sales and continued commercial progress, alongside a post-period equity fundraise...
ETHY

Ethtry reports strengthened balance sheet in 2025 results

Ethtry reported a 2025 loss of £619,270, while cash increased to £4.3 million following a £5.3 million fundraising, supporting its renewable energy strategy and post-year-end Ethereum treasury rollout...
BIOG

Praxis Precision Medicines wins FDA Breakthrough Status for rare epilepsy treatment

Praxis Precision Medicines has received FDA Breakthrough Therapy Designation for elsunersen, adding momentum to a rare epilepsy programme held in Biotech Growth Trust’s portfolio...
Cizzle Biotechnology Holdings plc

Cizzle Bio targets earlier detection in gastric cancer

Cizzle Bio is targeting the gastric cancer diagnostic gap with DEX-G2, a blood test designed to support earlier detection where routine screening is limited...
SPI

Spire Healthcare Group Plc Spire Healthcare receives further extension to PUSU deadline

Spire Healthcare says discussions with Toscafund continue, with the Takeover Panel consenting to a further extension of the offer deadline...
VRCI

Verici Dx secures New York State laboratory certification for Tutivia test

Verici Dx has obtained New York State clinical laboratory certification, completing authorisation for Tutivia across all 50 US states and the District of Columbia...
CIZ

Dr Allan Syms on Cizzle Biotechnology’s CIZ1B US accreditation

Cizzle Biotechnology Executive Chairman Dr Allan Syms discusses the CIZ1B early lung cancer test gaining CLIA accreditation in the US, marking a shift towards commercial adoption, royalty revenues, and wider international licensing opportunities...
Genflow Biosciences Plc

Healthspan becomes a clearer investment theme in preventive wellness

Healthspan is becoming a stronger investment theme as consumers focus on daily habits that support healthier ageing...
Load More

News and Interview Alerts

Subscribe Free

Company Presentations

Q&As

Hardman & Co

Green News

View all Sustainable sectors, Plcs and news >>  

Search

Search

Latest interviews

Broker Talk

Funds

View all Funds, Market Insights and news >> 

FTSE 100 News

UK Broker Ratings

Health

Latest Interviews

FTSE 100 News

FTSE 250 News

News and Interview Alerts

Subscribe Free

Company Presentations

Q&As

Hardman & Co

BrokerTalk

FTSE 100

Funds

View all Funds, Market Insights and news >> 

Green News

View all Sustainable sectors, Plcs and news >>  

UK Broker Ratings

Follow us on Social Media:

Home X-twitter Linkedin Facebook Spotify Apple